Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dehydrocholic Acid→

Dehydrocholic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
81-23-2
Molecular formula
C24H34O5
Molecular weight
402.5 g/mol
Drug class
Synthetic bile acidcholeretic agent
Mechanism of action
Increases bile flow by promoting hepatic bile secretion and biliary excretion. It is a bile-acid derivative used to increase bile volume rather than as a receptor-targeted systemic therapy.
Indications / reported uses
  • Historically used as a choleretic agent in selected hepatobiliary disorders in countries where dehydrocholic acid products remain authorised; current availability and clinical role are limited

Sources: NLM MeSH — Dehydrocholic acid · PubMed — Dehydrocholic acid choleretic pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dehydrocholic Acid Environmental Risk Assessment (ERA) (the Dehydrocholic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.